Skip to main content
. 2014 Apr 11;42(9):5765–5775. doi: 10.1093/nar/gku225

Figure 2.

Figure 2.

E6/E7 expression enhanced BMAL1 ubiquitination and proteasomal degradation through UBE3A. (A) Left panel: IB of steady state BMAL1 in WT and E6/E7 cells. Right panels: integrated density measurement of BMAL1 (n = 3, P < 0.05) and steady state Bmal1 gene expression by qPCR (n = 3, P > 0.05). **P < 0.01, see underlined. (B) Top panel: BMAL1 protein level following cycloheximide (20 μg/ml). Bottom panel: protein degradation rate. (C) Ubiquitination assay of V5-BMAL1 in HEK 293T cells by nickel affinity pull-down. Total levels of V5-BMAL1 in the input lysates are shown in the panel below. MG132 (5 μM) was applied in all cases. (D) V5-BMAL1 levels in HEK 293T cells, transfected with E6/E7, co-transfected with either HA-UBE3A or a dominant negative mutant (C833A). Representative, n = 3.